Suppr超能文献

膀胱癌标志物的敏感性和特异性——有那么简单吗?

Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?

作者信息

Roghmann Florian, Goebell Peter J, Dyrskjøt Lars, van Rhijn Bas W G, Käfferlein Heiko U, Hakenberg Oliver, Stenzl Arnulf, Burger Maximilian, Pesch Beate, Benderska-Söder Natalya, Schmitz-Dräger Bernd J

机构信息

Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.

Department of Urology and Pediatric Urology, Friedrich-Alexander University, Erlangen, Germany.

出版信息

Bladder Cancer. 2022 Mar 11;8(1):1-4. doi: 10.3233/BLC-211602. eCollection 2022.

Abstract

Marker research, and in particular urine bladder cancer marker research throughout the past three decades, devours enormous scientific resources in terms of manpower (not to mention time spent on reviewing and editorial efforts) and financial resources, finally generating large numbers of manuscripts without affecting clinical decision making. This is mirrored by the fact that current guidelines do not recommend marker use due to missing level 1 evidence. Although we recognize the problems and obstacles, the authors of this commentary feel that the time has come to abandon the current procedures and move on to prospective trial designs implementing marker results into clinical decision making. Our thoughts and concerns are summarized in this comment.

摘要

在过去三十年中,标志物研究,尤其是膀胱癌标志物研究,耗费了大量的人力科学资源(更不用说用于审阅和编辑工作的时间)和财力资源,最终产生了大量的手稿,却并未影响临床决策。目前的指南因缺乏一级证据而不推荐使用标志物,这一事实反映了上述情况。尽管我们认识到其中的问题和障碍,但本评论的作者认为,现在是时候摒弃当前的程序,转向将标志物结果纳入临床决策的前瞻性试验设计了。我们的想法和担忧总结于此评论中。

相似文献

1
Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?
Bladder Cancer. 2022 Mar 11;8(1):1-4. doi: 10.3233/BLC-211602. eCollection 2022.
2
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
3
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15.
5
Urine markers for detection and surveillance of bladder cancer.
Urol Oncol. 2014 Apr;32(3):222-9. doi: 10.1016/j.urolonc.2013.06.001. Epub 2013 Sep 17.
6
Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Urol Oncol. 2024 Aug;42(8):229-235. doi: 10.1016/j.urolonc.2024.01.025. Epub 2024 Feb 24.
9
Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.
Urol Oncol. 2021 Jan;39(1):41-51. doi: 10.1016/j.urolonc.2020.08.016. Epub 2020 Sep 9.
10
Current concepts of tumor markers in bladder cancer.
Urol Clin North Am. 2002 Feb;29(1):229-34. doi: 10.1016/s0094-0143(02)00008-3.

本文引用的文献

1
Extensive heterogeneity in somatic mutation and selection in the human bladder.
Science. 2020 Oct 2;370(6512):75-82. doi: 10.1126/science.aba8347.
2
Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
Urol Oncol. 2020 Dec;38(12):886-895. doi: 10.1016/j.urolonc.2020.01.006. Epub 2020 Mar 18.
3
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
4
Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.
Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验